Search
Biontech SE
BNTXAdd to Watchlist
93.015USD
+0.895+0.97%
Close 08-13 16:00（ET）Quotes delayed by 15 min
23.52BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-13The current earnings forecast score of Biontech SE is 7.90, ranking 263 out of 387 in the Biotechnology & Medical Research industry. The average price target is 140.00, with a high of 181.00 and a low of 82.11.
Analyst Rating
Based on
21
analysts
Buy
Current Rating
125.053
Target Price
+34.84%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Biontech SE
BNTX
21
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Biontech SE's expected revenue for the next quarter?
Biontech SE's expected revenue is 1.22B.
What is Biontech SE's price target?
Analysts forecast that Biontech SE's price target is USD 140.00, with the highest forecast at USD 181.00 and the lowest forecast at USD 82.11.
How have Biontech SEBNTX's recent earnings per share performed?
The market expectation was USD -3.70, while Biontech SEBNTX's earnings per share (EPS) for the previous quarter was USD -2.43. EPS for the next quarter is expected at USD 1.05.
What is the analyst rating for Biontech SE?
Based on the ratings of Biontech SE's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.